Company Matinas BioPharma Holdings Inc Other OTC

Equities

US5768101058

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Other OTC Other stock markets
- ^USD	-

06-24	Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program	CI
06-18	Transcript : Matinas BioPharma Holdings, Inc. - Special Call

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFÎ±.

USD in Million	2022	Weight	2023	Weight	Delta
Novel Pharmaceutical Products 100.0 %	3	100.0 %	1	100.0 %	-65.62%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	3	100.0 %	1	100.0 %	-65.62%

Managers	Title	Age	Since
Jerome Jabbour FOU	Founder	50	30/04/13
Keith Kucinski DFI	Director of Finance/CFO	55	02/01/19
Hui Liu CTO	Chief Tech/Sci/R&D Officer	56	30/11/20
James Ferguson CTO	Chief Tech/Sci/R&D Officer	70	24/02/19
Theresa Matkovits PRN	Corporate Officer/Principal	56	14/10/18
Thomas Hoover PRN	Corporate Officer/Principal	55	05/12/21

Members of the board	Title	Age	Since
Herbert Conrad FOU	Founder	91	30/04/13
Natasha Giordano BRD	Director/Board Member	62	13/09/20
Eric Ende CHM	Chairman	55	02/04/17
James Scibetta BRD	Director/Board Member	59	31/10/13
Matthew Wikler BRD	Director/Board Member	74	31/12/17
Kathryn Corzo BRD	Director/Board Member	63	31/08/21
Jerome Jabbour FOU	Founder	50	30/04/13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	250,816,164	244,482,252 ( 97.47 %)	0	97.47 %

Name	Equities	%	Valuation
Vanguard Global Advisers LLC 3.715 %	9,317,838	3.715 %	1 M $
Herbert Conrad 1.872 %	4,694,566	1.872 %	741 741 $
Sargent Investment Group LLC 1.440 %	3,610,500	1.440 %	570 459 $
BlackRock Institutional Trust Co. NA 0.9897 %	2,482,400	0.9897 %	392 219 $
Geode Capital Management LLC 0.8514 %	2,135,457	0.8514 %	337 402 $
Alliance Wealth Management Group LLC 0.7522 %	1,886,715	0.7522 %	298 101 $
Arkadios Wealth Advisors LLC 0.6475 %	1,624,000	0.6475 %	256 592 $
Neville, Rodie & Shaw, Inc. 0.4614 %	1,157,332	0.4614 %	182 858 $
JTC Employer Solutions Trustee Ltd. 0.3090 %	775,000	0.3090 %	122 450 $
STATE STREET CORPORATION 0.2631 %	659,871	0.2631 %	104 260 $

Matinas BioPharma Holdings, Inc.

1545 Route 206 South Suite 302

07921-9999, Bedminster

+908 484 8805

http://www.matinasbiopharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.38%	127B
REGENERON PHARMACEUTICALS, INC.	+24.59%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.93%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-14.83%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+12.68%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+56.49%	14.43B

Bio Therapeutic Drugs